Lidocaine serum concentration after epidural administration in combination with morphine and fentanyl in rabbit--a preliminary study.

Morphine and fentanyl are often used as adjuvants in epidural anesthesia to prolong analgesia. The aim of this study was to evaluate the impact of addition of morphine or fentanyl to lidocaine on serum lidocaine concentrations in rabbits after epidural administration. During general anesthesia, rabbits of the group L received epidurally 2% lidocaine, rabbits of the group LM 2% lidocaine and morphine, and rabbits of the group LF 2% lidocaine and fentanyl. Blood for determination of serum lidocaine concentration was taken before anesthesia and in first 90 min after epidural administration. After 5, 10, and 25 min in the group L the lidocaine serum concentrations were the lowest, while in the group LM the lidocaine serum concentrations were the highest. Morphine and fentanyl did not cause significant changes of serum lidocaine concentration in rabbits and may be used as adjuvant in epidural anesthesia without significant increase in lidocaine absorption from epidural space.

Therapy of nonalcoholic fatty liver disease: current status.

Nonalcoholic fatty liver disease (NAFLD), the hepatic manifestation of the metabolic syndrome, has become a common entity in clinical practice. In most of the patients it presents as simple steatosis with nonprogressive clinical course. However, some patients have progressive form of NAFLD, nonalcoholic steatohepatitis (NASH), and are at increased risk of developing cirrhosis and hepatocellular carcinoma. NAFLD treatment includes lifestyle modifications and pharmacotherapy aiming at increasing insulin sensitivity, and attenuating inflammation and hepatic fibrosis. Weight reduction has consistently been shown to reduce levels of liver enzymes and insulin resistance. Although dietary intervention and exercise remain the first-line therapy, due to low patients compliance to these measures pharmacotherapy or surgical approaches are often required. Metformin and thiazolidinediones may improve insulin sensitivity, serum aminotransferase level and liver histology. However, little evidence exists regarding their sustained effects after drug discontinuation which, together with their side effects, limits their widespread use in clinical practice. Statins appear to be safe agents for the treatment of hyperlipidemia, although trials documenting their efficacy in NAFLD are scarce. Based on the recent clinical trials, weight loss medication orlistat, ursodeoxycholic acid and antioxidant agents could potentially be used as adjunctive therapy. Considering still largely controversial clinical data regarding pharmacological agents, their high cost and known side-effects, lifestyle modifications at present remain the only essential considerations in the NAFLD treatment.

Pericarditis in exacerbation of ulcerative colitis.

Acute pericarditis occurs very rarely in association with inflammatory bowel disease (IBD). It has been described both as an extraintestinal manifestation of IBD and as an adverse drug reaction in IBD treatment. We present a case of a 26-year-old female patient with a severe exacerbation of ulcerative colitis, who was previously under long-term treatment with mesalazine and low-dose prednisone. The literature on pericardial involvement in IBD is reviewed.